Oncolytics Biotech® Inc. Announces Addition to Senior Management Team

Oncolytics Biotech® Inc. Announces Addition to Senior Management Team 
CALGARY, Feb. 20, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the 
"Company") (TSX: ONC, NASDAQ: ONCY) today announced the appointment of Dr. 
Jeremy Grushcow to the role of General Counsel. 
Dr. Grushcow has more than ten years' experience in the legal profession 
representing public and private entities, as well as venture capital and 
private equity firms in the acquisition, financing, development, operation and 
sale of pharmaceutical and life sciences companies in the U.S. and Canada. He 
holds a B.Sc. from the University of Toronto, a Ph.D. in molecular genetics 
and cell biology from the University of Chicago, and a J.D. with honors from 
the University of Chicago Law School. He has been admitted to the Bar in 
Ontario, New York and Illinois. Prior to joining Oncolytics, Dr. Grushcow was 
a partner in the Norton Rose LLP pharmaceuticals and life sciences group. He 
also previously held positions in the Shearman & Sterling LLP capital markets 
group and the Kirkland & Ellis LLP intellectual property transactions group. 
"We are delighted to welcome Jeremy to our management team," said Dr. Brad 
Thompson, President and CEO of Oncolytics. "He brings a unique combination of 
scientific, legal and business expertise that will support Oncolytics' 
continued evolution and we look forward to benefiting from his specific 
experience and insight." 
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials using REOLYSIN(®), its proprietary 
formulation of the human reovirus. For further information about Oncolytics, 
please visit: www.oncolyticsbiotech.com. 
This press release contains forward-looking statements within the meaning of 
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act 
of 1934, as amended, and forward-looking information within the meaning of 
Canadian securities laws. Statements, other than statements of historical 
facts, included in this press release that address activities, events or 
developments that Oncolytics expects or anticipates will or may occur in the 
future, including such things as the appointment and performance of a General 
Counsel, the Company's belief as to the potential of REOLYSIN as a cancer 
therapeutic, and other such matters are forward-looking statements and 
forward-looking information and involve known and unknown risks and 
uncertainties, which could cause the Company's actual results to differ 
materially from those in the forward-looking statements and forward-looking 
information. Such risks and uncertainties include, among others, risks related 
to the statistical sufficiency of patient enrollment numbers in separate 
patient groups, the availability of funds and resources to pursue research and 
development projects, the efficacy of REOLYSIN as a cancer treatment, the 
tolerability of REOLYSIN outside a controlled test, the success and timely 
completion of clinical studies and trials, the Company's ability to 
successfully commercialize REOLYSIN, uncertainties related to the research and 
development of pharmaceuticals and uncertainties related to the regulatory 
process. Investors should consult the Company's quarterly and annual filings 
with the Canadian and U.S. securities commissions for additional information 
on risks and uncertainties relating to the forward-looking statement and 
forward-looking information. Investors are cautioned against placing undue 
reliance on forward-looking statements and forward-looking information. The 
Company does not undertake to update these forward-looking statements and 
forward-looking information, except as required by applicable laws. 
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta 
T2P 3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@equicomgroup.com 
Dian Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 
10012 Tel: 212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com   
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Oncolytics Biotech Inc.
ST: Alberta
NI: BTC 2575 WNEWS  
-0- Feb/20/2013 22:00 GMT
Press spacebar to pause and continue. Press esc to stop.